IL142531A0 - Cyclic peptide compound, processes for the preparation thereof and pharmaceutical compositions containing the same - Google Patents
Cyclic peptide compound, processes for the preparation thereof and pharmaceutical compositions containing the sameInfo
- Publication number
- IL142531A0 IL142531A0 IL14253199A IL14253199A IL142531A0 IL 142531 A0 IL142531 A0 IL 142531A0 IL 14253199 A IL14253199 A IL 14253199A IL 14253199 A IL14253199 A IL 14253199A IL 142531 A0 IL142531 A0 IL 142531A0
- Authority
- IL
- Israel
- Prior art keywords
- processes
- preparation
- same
- pharmaceutical compositions
- compositions containing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
- C07K5/126—Tetrapeptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPP6469A AUPP646998A0 (en) | 1998-10-13 | 1998-10-13 | Novel compound wf27082b substance |
AUPP9257A AUPP925799A0 (en) | 1999-03-16 | 1999-03-16 | Novel compound WF27082 |
PCT/JP1999/005597 WO2000021979A2 (en) | 1998-10-13 | 1999-10-08 | Cyclic tetrapeptide and their use as histone deacetylase inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
IL142531A0 true IL142531A0 (en) | 2002-03-10 |
Family
ID=25645895
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL14253199A IL142531A0 (en) | 1998-10-13 | 1999-10-08 | Cyclic peptide compound, processes for the preparation thereof and pharmaceutical compositions containing the same |
Country Status (15)
Country | Link |
---|---|
US (1) | US6656905B1 (ko) |
EP (1) | EP1123309A2 (ko) |
JP (1) | JP2002527449A (ko) |
KR (1) | KR20010080142A (ko) |
CN (1) | CN1330660A (ko) |
BR (1) | BR9914779A (ko) |
CA (1) | CA2346943A1 (ko) |
CZ (1) | CZ20011342A3 (ko) |
HK (1) | HK1042308A1 (ko) |
HU (1) | HUP0103985A2 (ko) |
IL (1) | IL142531A0 (ko) |
PL (1) | PL348648A1 (ko) |
TR (1) | TR200101049T2 (ko) |
TW (1) | TW536544B (ko) |
WO (1) | WO2000021979A2 (ko) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0005199D0 (en) * | 2000-03-04 | 2000-04-26 | Imp College Innovations Ltd | Modulation of histone deacetylase |
JP2004509941A (ja) | 2000-09-29 | 2004-04-02 | プロリフィクス リミテッド | Hdacインヒビターとしてのアミド結合を含むカルバミン酸化合物 |
WO2002055017A2 (en) | 2000-11-21 | 2002-07-18 | Wake Forest University | Method of treating autoimmune diseases |
JP4638148B2 (ja) * | 2001-10-16 | 2011-02-23 | スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ | 神経変性疾患および脳の癌の処置 |
CA2471957A1 (en) * | 2001-12-28 | 2003-07-17 | Fujisawa Pharmaceutical Co., Ltd. | Cyclic tetrapeptide compound and use thereof |
WO2003070188A2 (en) * | 2002-02-15 | 2003-08-28 | Sloan-Kettering Institute For Cancer Research | Method of treating trx mediated diseases |
CN1646558B (zh) * | 2002-02-20 | 2010-05-12 | 国立大学法人九州工业大学 | 组蛋白脱乙酰酶抑制剂 |
US7148257B2 (en) | 2002-03-04 | 2006-12-12 | Merck Hdac Research, Llc | Methods of treating mesothelioma with suberoylanilide hydroxamic acid |
US7456219B2 (en) | 2002-03-04 | 2008-11-25 | Merck Hdac Research, Llc | Polymorphs of suberoylanilide hydroxamic acid |
WO2003075839A2 (en) | 2002-03-04 | 2003-09-18 | Aton Pharma, Inc. | Methods of inducing terminal differentiation |
JP2005518817A (ja) | 2002-03-07 | 2005-06-30 | ユニバーシティー、オブ、デラウェア | ヒストン・デアセチラーゼ・インヒビタ、ラムダファージベータ蛋白、またはヒドロキシウレアを含む組成物を使用してオリゴヌクレオチド媒介性核酸配列改変を高める方法、組成物およびキット |
JP2005530734A (ja) * | 2002-04-15 | 2005-10-13 | スローン − ケッタリング インスティチュート フォー キャンサー リサーチ | 癌の処置のための併用療法 |
US7154002B1 (en) | 2002-10-08 | 2006-12-26 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
US7250514B1 (en) | 2002-10-21 | 2007-07-31 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
WO2004043352A2 (en) * | 2002-11-12 | 2004-05-27 | Alcon, Inc. | Histone deacetylase inhibitors for the treatment of ocular neovascular or edematous disorders and diseases |
FR2847817B1 (fr) * | 2002-11-28 | 2006-11-10 | Centre Nat Rech Scient | Utilisation d'un inhibiteur d'histone deacetylase pour le traitement des dystrophies musculaires |
US8299126B2 (en) * | 2003-02-27 | 2012-10-30 | Leonard A. Cohen | Treatment of canine hemangiosarcoma with a histone deacetylase inhibitor |
US7381825B2 (en) | 2003-03-17 | 2008-06-03 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
US7662778B2 (en) | 2003-06-20 | 2010-02-16 | Riken | Histone deacetylase inhibitor and process for producing the same |
EP1491188A1 (en) * | 2003-06-25 | 2004-12-29 | G2M Cancer Drugs AG | Topical use of valproic acid for the prevention or treatment of skin disorders |
WO2005013958A1 (en) * | 2003-08-07 | 2005-02-17 | Novartis Ag | Histone deacetylase inhibitors as immunosuppressants |
KR100924737B1 (ko) | 2003-08-26 | 2009-11-04 | 슬로안-케테링인스티튜트퍼캔서리서치 | Hdac 억제제를 이용한 암의 치료 방법 |
JP2007504131A (ja) | 2003-08-29 | 2007-03-01 | エートン ファーマ インコーポレーティッド | 癌の組み合わせ処置法 |
EP1810028A2 (en) * | 2004-10-14 | 2007-07-25 | Rigel Pharmaceuticals, Inc. | Heterocyclic inhibitors of ires-mediated translation and methods of use thereof |
EP1824831A2 (en) | 2004-12-16 | 2007-08-29 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
US20080213399A1 (en) * | 2005-02-03 | 2008-09-04 | Topotarget Uk Limited | Combination Therapies Using Hdac Inhibitors |
EP1896436A2 (en) | 2005-05-11 | 2008-03-12 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
JP5108750B2 (ja) | 2005-05-13 | 2012-12-26 | トポターゲット ユーケー リミテッド | Hdac阻害剤の医薬製剤 |
TWI415603B (zh) | 2005-05-20 | 2013-11-21 | Merck Sharp & Dohme | 1,8-辛二醯基苯胺羥胺酸(suberoylanilide hydroxamic acid)之調配物及其製配方法 |
BRPI0613429A2 (pt) | 2005-07-14 | 2009-02-10 | Takeda San Diego Inc | inibidores de histona desacetilase |
EP1957056A2 (en) * | 2005-11-10 | 2008-08-20 | TopoTarget UK Limited | Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer alone or in combination with chemotherapeutic agent |
CA2649877A1 (en) | 2006-04-24 | 2007-12-21 | Gloucester Pharmaceuticals | Gemcitabine combination therapy |
WO2007146730A2 (en) | 2006-06-08 | 2007-12-21 | Gloucester Pharmaceuticals | Deacetylase inhibitor therapy |
KR101114970B1 (ko) | 2006-09-05 | 2012-03-13 | 도꾸리쯔교세이호징 리가가쿠 겐큐소 | 히스톤 탈아세틸화효소 저해 활성을 갖는 화합물, 및 이 화합물을 활성 성분으로 포함하는 의약 |
US20090022720A1 (en) * | 2007-07-20 | 2009-01-22 | Stephan Fischer | Conjugate of an antibody against CD4 and antifusogenic peptides |
CN101868446A (zh) * | 2007-09-25 | 2010-10-20 | 托波塔吉特英国有限公司 | 某些异羟肟酸化合物的合成方法 |
CA2706750A1 (en) * | 2007-11-27 | 2009-06-04 | Ottawa Health Research Institute | Amplification of cancer-specific oncolytic viral infection by histone deacetylase inhibitors |
WO2009109861A1 (en) * | 2008-03-07 | 2009-09-11 | Topotarget A/S | Methods of treatment employing prolonged continuous infusion of belinostat |
US20110104175A1 (en) * | 2008-06-03 | 2011-05-05 | Cedars-Sinai Medical Center | Methods of treatment for pulmonary fibrosis |
GB0900555D0 (en) * | 2009-01-14 | 2009-02-11 | Topotarget As | New methods |
PL219569B1 (pl) | 2010-02-19 | 2015-05-29 | Peptaderm Spółka Z Ograniczoną Odpowiedzialnością | Cykliczne tetrapeptydy i ich zastosowanie |
CN102153622A (zh) * | 2010-12-25 | 2011-08-17 | 中国水产科学研究院珠江水产研究所 | 一种免疫增强剂脯氨酸-甘氨酸环四肽(c14h20n4o4)及应用 |
CN107141335B (zh) * | 2017-04-12 | 2020-10-20 | 宁波大学 | 一种环肽化合物及其制备方法和应用 |
EP3461488A1 (en) | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dbait molecule and a hdac inhibitor for treating cancer |
EP3461480A1 (en) | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
EP4405680A1 (en) | 2021-09-20 | 2024-07-31 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor |
WO2023194441A1 (en) | 2022-04-05 | 2023-10-12 | Istituto Nazionale Tumori Irccs - Fondazione G. Pascale | Combination of hdac inhibitors and statins for use in the treatment of pancreatic cancer |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07196686A (ja) | 1994-01-06 | 1995-08-01 | Takeda Chem Ind Ltd | 化合物tan−1746類、その製造法および用途 |
EP0855024A4 (en) * | 1995-09-20 | 2001-08-22 | Merck & Co Inc | HISTONE DEACETYLASE AS THE ATTACK POINT FOR ANTIPROTOZOIC ACTIVE SUBSTANCES |
GB2309696B (en) | 1996-01-31 | 2000-02-23 | Merck & Co Inc | Antiprotozoal cyclic tetrapeptides |
US6777217B1 (en) | 1996-03-26 | 2004-08-17 | President And Fellows Of Harvard College | Histone deacetylases, and uses related thereto |
AUPP505798A0 (en) | 1998-08-04 | 1998-08-27 | Fujisawa Pharmaceutical Co., Ltd. | Novel compound fr225497 substance |
-
1999
- 1999-10-08 HU HU0103985A patent/HUP0103985A2/hu unknown
- 1999-10-08 WO PCT/JP1999/005597 patent/WO2000021979A2/en not_active Application Discontinuation
- 1999-10-08 CN CN99814383A patent/CN1330660A/zh active Pending
- 1999-10-08 EP EP99970393A patent/EP1123309A2/en not_active Withdrawn
- 1999-10-08 KR KR1020017004664A patent/KR20010080142A/ko not_active Application Discontinuation
- 1999-10-08 TR TR2001/01049T patent/TR200101049T2/xx unknown
- 1999-10-08 CA CA002346943A patent/CA2346943A1/en not_active Abandoned
- 1999-10-08 BR BR9914779-3A patent/BR9914779A/pt not_active IP Right Cessation
- 1999-10-08 IL IL14253199A patent/IL142531A0/xx unknown
- 1999-10-08 PL PL99348648A patent/PL348648A1/xx not_active Application Discontinuation
- 1999-10-08 CZ CZ20011342A patent/CZ20011342A3/cs unknown
- 1999-10-08 JP JP2000575884A patent/JP2002527449A/ja not_active Abandoned
- 1999-10-08 US US09/806,500 patent/US6656905B1/en not_active Expired - Fee Related
- 1999-10-11 TW TW088117518A patent/TW536544B/zh not_active IP Right Cessation
-
2002
- 2002-05-28 HK HK02103971.5A patent/HK1042308A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
CZ20011342A3 (cs) | 2001-09-12 |
KR20010080142A (ko) | 2001-08-22 |
PL348648A1 (en) | 2002-06-03 |
HK1042308A1 (zh) | 2002-08-09 |
US6656905B1 (en) | 2003-12-02 |
TR200101049T2 (tr) | 2002-01-21 |
CA2346943A1 (en) | 2000-04-20 |
CN1330660A (zh) | 2002-01-09 |
HUP0103985A2 (hu) | 2002-02-28 |
EP1123309A2 (en) | 2001-08-16 |
WO2000021979A2 (en) | 2000-04-20 |
WO2000021979A3 (en) | 2000-07-20 |
TW536544B (en) | 2003-06-11 |
JP2002527449A (ja) | 2002-08-27 |
BR9914779A (pt) | 2001-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL142531A0 (en) | Cyclic peptide compound, processes for the preparation thereof and pharmaceutical compositions containing the same | |
IL138280A0 (en) | 20-KETO-11β-ARYLSTERIODS, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND METHODS FOR THE PREPARATION THEREOF | |
IL144910A0 (en) | Cyclic compounds and pharmaceutical compositions containing the same | |
HUP0102372A3 (en) | Dihydropyrimidines, preparation thereof and pharmaceutical compositions containing the same | |
HUP0101800A3 (en) | Novel substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | |
IL145013A0 (en) | Tricyclic compounds, processes for the preparation thereof and pharmaceutical compositions containing the same | |
GB9113219D0 (en) | Peptide compound,processes for preparation thereof and pharmaceutical composition comprising the same | |
HUP0100950A3 (en) | Cyclic amino compounds, use of them for producing pharmaceutical compositions and pharmaceutical compositions containing them | |
IL140897A0 (en) | Benzocycloheptene derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same | |
IL116211A0 (en) | Peptide compounds pharmaceutical compositions containing the same and processes for the preparation thereof | |
IL136938A0 (en) | 11β-HALOGEN-7α-SUBSTITUTED ESTRATRIENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND METHODS FOR THE PREPARATION THEREOF | |
HUP0103265A3 (en) | Cyclic prosaposin-derived peptides, pharmaceutical compositions comprising thereof and their use | |
HUP0102483A3 (en) | Pharmaceutical compositions containing androst-5-ene-3betha,17betha-diol | |
IL143801A0 (en) | (hetero) aryl-bicyclic heteroaryl derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same | |
IL131415A (en) | Anti-inflammatory compounds, processes for their preparation and pharmaceutical compositions comprising them | |
HUP0001539A3 (en) | 2-(1-iminoethylamino)ethyl-homocysteine, process for its preparation and pharmaceutical compositions containing the same | |
HUP0100601A3 (en) | Bicyclic compounds containing nitrogen, processes for their preparation and pharmaceutical compositions thereof | |
HUP0201376A2 (en) | Thiazoloderivatives and pharmaceutical compositions containing them and process for preparation the compounds | |
IL106600A0 (en) | Peptides,pharmaceutical compositions containing the same and processes for the preparation thereof | |
AU4710499A (en) | Cyclic amino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use ofsuch compounds | |
IL139529A0 (en) | Platinum complexes, processes for the preparation thereof and pharmaceutical compositions containing the same | |
IL137494A0 (en) | Polypeptide compounds, process for the preparation thereof and pharmaceutical compositions containing the same | |
HUP0000851A3 (en) | Novel pyrimidine derivatives, processes for the preparation thereof and pharmaceutical compositions containing them | |
HUP0102676A3 (en) | Solid, quick dissolving pharmaceutical compositions containing cetrizine | |
HUP0102215A3 (en) | Benzoylpyridazines, pharmaceutical compositions containing the same and process for their preparation |